IMUNON’s VP of R&D to Present at the Vaccines Summit-2023
2023年11月14日 - 11:00PM
IMUNON, Inc. (NASDAQ: IMNN), a
clinical-stage biotechnology company focused on harnessing the
power of the immune system against cancer and infectious diseases,
announces that Jean Boyer, Ph.D., vice president of preclinical
research and development, will highlight the Company’s vaccine
development work in a presentation at the Vaccines Summit-2023
underway in Boston. Dr. Boyer will present “Robust Immunogenicity
and Protection with PlaCCine: A Novel DNA Vaccine Delivered with a
Functionalized Polymeric Delivery System” during the “New Vaccine
Development” session this afternoon. The presentation may be viewed
on the Company’s website in the Scientific Presentations section
here.
Her presentation includes updated data related
to IMUNON’s PlaCCine SARS-CoV-2 DNA vaccine, including studies
showing PlaCCine expresses spike proteins in mice and primates
demonstrating induction of spike-specific neutralizing antibody
responses and CD8 and CD4 spike-specific cellular responses. The
induced immune responses in vaccinated mice were maintained for up
to 14 months after vaccination. Research being presented also shows
that in both primates and mice, the induced immune responses
reduced lung viral loads by more than 90%. In mouse studies, robust
immune responses were observed following a single intramuscular
injection of either PlaCCine SARS-CoV-2 DNA vaccine or a novel
PlaCCine Lassa Virus DNA vaccine.
“Through Dr. Boyer’s presentation we continue to
inform the scientific community about the compelling data we are
generating with our PlaCCine modality, notably the long duration of
protection observed after vaccination, which is what you want to
see in a next-generation vaccine. Our non-viral DNA vaccine
presentation complements nicely the Summit’s theme ‘next-generation
vaccines treatment and diagnostics that save lives,’” said Dr.
Corinne Le Goff, president and chief executive officer of IMUNON.
“Importantly, PlaCCine DNA vaccines demonstrate stability over at
least 12 months at 4°C and for one month at 25°C. As such, PlaCCine
vaccines could be easily deployed to help contain outbreaks such
Lassa fever, EBOLA or Marburg that occur in resource-challenged
parts of the world. We look forward to continuing our development
of PlaCCine with its potential to impact global health.”
About IMUNON
IMUNON is a fully integrated, clinical stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies. IMUNON is developing its non-viral DNA
technology across four modalities. The first modality, TheraPlas™,
is developed for the coding of proteins and cytokines in the
treatment of solid tumors where an immunological approach is deemed
promising. The second modality, PlaCCine™, is developed for the
coding of viral antigens that can elicit a strong immunological
response. This technology may represent a promising platform for
the development of vaccines in infectious diseases. The third
modality, FixPlas™, concerns the application of our DNA technology
to produce universal cancer vaccines also called tumor associated
antigen cancer vaccines. Finally, the fourth modality, which is
still in the discovery phase, IndiPlas™, will focus on the
development of personalized cancer vaccines, or neoepitope cancer
vaccines.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting IND-enabling preclinical studies for the development of
a COVID-19 booster vaccine: IMNN-101. The Company has also
initiated preclinical studies to develop a Trp2 tumor associated
antigen cancer vaccine in melanoma: IMNN-201. We will continue to
leverage these modalities and to advance the technological frontier
of plasmid DNA to better serve patients with difficult-to-treat
conditions. For more information on IMUNON,
visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s periodic reports
and prospectuses filed with the Securities and Exchange Commission.
IMUNON assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
609-482-2455 |
Kgolodetz@lhai.com |
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 4 2024 まで 5 2024
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 5 2023 まで 5 2024